作者
Eleonora Vianello, Patricia Gonzalez-Dias, Suzanne van Veen, Carmen G Engele, Edwin Quinten, Thomas P Monath, Donata Medaglini, Selidij T Agnandij, Rafi Ahmed, Jenna Anderson, Floriane Auderset, Philip Bejon, Luisa Borgianni, Jessica Brosnahan, Annalisa Ciabattini, Olivier Engler, Mariëlle C Haks, Ali M Harandi, Donald G Heppner, Alice Gerlini, Angela Huttner, Peter G Kremsner, Francis M Ndungu, Patricia Njuguna, Tom HM Ottenhoff, David Pejoski, Mark Page, Gianni Pozzi, Francesco Santoro, Claire-Anne Siegrist, Sheri Dubey, Michael Eichberg, Essone P Ndong, Kabwende Lumeka, Helder I Nakaya, Patricia Gonzales Dias Carvalho, Sylvia Rothenberger, Sravya S Nakka, Paulin N Essone, Selidji Todagbe Agnandji
发表日期
2022/2/1
期刊
The Lancet Microbe
卷号
3
期号
2
页码范围
e113-e123
出版商
Elsevier
简介
Background
A recombinant vesicular stomatitis virus vector expressing the Zaire Ebola virus glycoprotein (rVSVΔG-ZEBOV-GP) vaccine has been reported as safe, immunogenic, and highly protective in a ring vaccination trial. We aimed to identify transcriptomic immune response biomarker signatures induced by vaccination and associated signatures with its immunogenicity and reactogenicity to better understand the potential mechanisms of action of the vaccine.
Methods
354 healthy adult volunteers were vaccinated in randomised, double-blind, placebo-controlled trials in Europe (Geneva, Switzerland [November, 2014, to January, 2015]) and North America (USA [Dec 5, 2014, to June 23, 2015]), and dose-escalation trials in Africa (Lambaréné, Gabon [November, 2014, to January, 2015], and Kilifi, Kenya [December, 2014, to January, 2015]) using different doses of the recombinant vesicular stomatitis virus vector …
学术搜索中的文章
E Vianello, P Gonzalez-Dias, S van Veen, CG Engele… - The Lancet Microbe, 2022